Fungal Endemicity: Beyond the Classic Geographic Map

1. Introdcution

For decades, clinicians have been taught to consider the three thermally dimorphic endemic fungi - Histoplasma capsulatum, Blastomyces dermatitidis/gilchristii, and Coccidioides immitis/posadasii - primarily in the context of travel to specific endemic regions. These teaching zones, largely derived from histoplasmin skin-test surveys conducted in the mid-20th century, became codified in clinical guidelines and, more enduringly, in the mental models of practicing physicians [1,2]. The consequence has been a diagnostic filter that excludes geography-naïve patients from timely testing, perpetuates diagnostic delays averaging 29 days, and results in preventable morbidity.

A convergence of modern surveillance data, climate modeling, and immunosuppression epidemiology has rendered the classic geographic framework increasingly obsolete. This review summarizes current evidence on the shifting landscape of endemic mycoses, examines the drivers behind geographic expansion, quantifies the cost of diagnostic delay, and proposes a practical, geography-independent approach for pulmonologists and critical care physicians. It further incorporates updated guidance from the 2025 IDSA Histoplasmosis Guideline Update — the first revision since 2007 [12].

2. The Classic Endemic Zone Framework: How It Was Built and Why It Fails

The geographic boundaries taught in medical schools were constructed from limited early-20th-century skin-test surveys and soil sampling biased toward clinical case clusters in the Ohio and Mississippi River Valleys for histoplasmosis, the Great Lakes basin for blastomycosis, and the Lower Sonoran Life Zone for coccidioidomycosis [1,3]. Crucially, these maps reflect where investigators looked and where reporting infrastructure existed - not the true distribution of these organisms. Inconsistent state-level reporting requirements (blastomycosis is not reportable in most US states even today) have compounded this undercount for decades.

The practical consequence is that geography has functioned as a diagnostic pre-filter: a negative travel history to a classic endemic zone reduces clinical suspicion before testing is even considered. For an immunosuppressed patient in Houston, Seattle, or New York, this filter may be the single greatest barrier to timely diagnosis.

3. Contemporary Epidemiology: A Paradigm Shift

3.1. Histoplasmosis

Mody et al. (Annals of Internal Medicine, 2023) analyzed Medicare beneficiary claims from 2007–2016 and documented clinically significant histoplasmosis incidence in 47 of 50 US states [4]. States outside the classic endemic zone - including Florida, Texas, Georgia, and New York - demonstrated incidences previously considered negligible. Approximately 30% of cases diagnosed in non-endemic states had no identifiable travel history to traditional endemic areas, suggesting true locally acquired disease. Histoplasma capsulatum has now been documented on all seven continents, including Antarctica [4,13].

3.2. Coccidioidomycosis

Caceres et al. (Clinical Infectious Diseases, 2023) identified 29 counties with significant coccidioidomycosis burden outside the classically defined Arizona and Central California zones, including newly recognized foci in the Pacific Northwest, central Utah, and Colorado [5]. Three autochthonous cases were confirmed in Washington State — more than 1,000 miles from the nearest classic endemic area. Climate modeling by Gorris et al. (GeoHealth, 2019) projects that under moderate warming scenarios (RCP 4.5), the Coccidioides-endemic range will expand from 12 to 17 states by 2035, potentially exposing 17 million additional people and generating up to $1.8 billion in additional annual healthcare costs by 2100 [6]. Under high-emissions projections (RCP 8.5), endemicity may extend to 28+ states by 2100.

3.3. Blastomycosis

EHR-based national analyses (2013–2023) document a doubling of blastomycosis incidence over a single decade, with extraordinary hotspot rates in Wisconsin (9.9/100,000), Arkansas (10.7/100,000), and Michigan [7]. The 2022–2023 Michigan paper mill outbreak - the largest documented blastomycosis outbreak in US history - involved 136 confirmed cases and 6 deaths in a largely indoor industrial workplace [8]. New signals are now emerging from Tennessee, Virginia, and North Carolina.

4. Drivers of Geographic Expansion

4.1. Climate Change

Rising temperatures and shifting precipitation patterns directly expand the ecological niches hospitable to Coccidioides and Histoplasma. The Gorris climate model demonstrates a strong, quantifiable relationship between temperature, drought severity, and Coccidioides range expansion already observed in real-world case data [6]. Temperature projections from IPCC AR6 suggest median surface warming of 1.5–4.0 °C across the continental US by 2100 [15].

4.2. Expanding Immunosuppressed Host Populations

TNF-α inhibitors confer a 25–100-fold increased risk of disseminated histoplasmosis and coccidioidomycosis compared to the general population [14]. The rapid growth of biologic therapy, solid organ and hematopoietic stem cell transplantation, CAR-T cell therapy, and checkpoint inhibitor use has created an expanding population of profoundly vulnerable hosts distributed across every geographic region. Between 2015 and 2023, the number of US patients receiving biologic immunomodulatory therapy increased by approximately 40%, reaching an estimated 3.5 million individuals [16].

4.3. Improved Diagnostics and Detection Bias

Urine antigen enzyme immunoassay (EIA) testing (MVista Histoplasma Quantitative EIA; IMMY) now offers same-day results with sensitivities of 85–90% for pulmonary disease and >95% for disseminated disease [13]. Wider availability of these tests has unmasked previously missed cases. Importantly, Blastomyces antigen cross-reacts with the Histoplasma antigen assay in approximately 90% of cases; both antigens should therefore always be ordered simultaneously [13].

5. The Cost of Delayed Diagnosis

Azar et al. (Open Forum Infectious Diseases, 2025) examined 384 confirmed endemic mycosis cases presenting to a non-endemic referral center between 2010 and 2022 [10]. The median time from symptom onset to correct diagnosis was 21 days (range 3–180 days); 62% of patients experienced a clinically meaningful delay. Forty-two percent were initially misdiagnosed - most commonly as bacterial pneumonia (28%), malignancy (10%), or sarcoidosis (4%). Patients with delayed diagnosis accumulated an average of $15,648 in excess healthcare costs. Absence of documented travel to a classic endemic zone was the strongest independent risk factor for delay (OR 4.2, 95% CI 2.1–8.3) [10].

A particularly dangerous pathway is the steroid cascade: a patient with unrecognized endemic fungal infection is diagnosed with sarcoidosis or inflammatory lung disease and started on corticosteroids. High-dose steroids in the context of active histoplasmosis or blastomycosis accelerate dissemination and worsen outcomes; this pattern has been documented in approximately 40% of initially misdiagnosed histoplasmosis cases [11]. Interrupting the steroid cascade through earlier fungal testing is among the highest-yield clinical interventions available to pulmonologists.

6. A Geography-Independent Diagnostic Framework

Contemporary evidence supports shifting the clinical diagnostic trigger from “Did the patient travel to an endemic zone?” to a risk-based framework anchored on immune status and clinical pattern. The following patients warrant urine antigen testing regardless of geographic history:

TIER 1 Test Immediately:

• • Any immunocompromised patient (TNF-α inhibitor, transplant recipient, HIV/AIDS, hematologic malignancy) presenting with community-acquired pneumonia or pulmonary infiltrates

TIER 2 Test Early:

• • CAP failing to respond to appropriate antibiotics after 2 weeks
• • Subacute or chronic pulmonary infiltrates with systemic features (weight loss, fever, night sweats)

TIER 3 Consider Testing:

• • Mediastinal lymphadenopathy with pulmonary infiltrate being worked up for sarcoidosis before antifungal testing
• • Significant occupational soil/dust exposure: construction, agriculture, excavation, landscaping

Urine antigen should be the first-line test for histoplasmosis and blastomycosis given its non-invasive nature, rapid turnaround, and high sensitivity in moderate-to-severe disease [13]. Coccidioides lacks a validated urine antigen; IgM and IgG serology (ID and CF methods) remain the cornerstone of cocci diagnosis. The IDSA 2025 Histoplasmosis Update explicitly moves away from geographic history as a prerequisite for testing, endorsing urine antigen as a strong recommendation for moderate/severe and immunocompromised patients [12].

7. Diagnostic Toolkit

Table 1. Diagnostic toolkit for endemic mycoses. 

Test	Pathogen	Sensitivity	Clinical Notes	Ref.
Urine antigen EIA (MVista/IMMY)	Histoplasma	85–90% pulm.; >95% dissem.	First-line; same-day; cross-reacts with Blastomyces	[13]
Urine antigen EIA	Blastomyces	~90% moderate-severe	Always order with Histo antigen simultaneously	[13]
IgM + IgG serology (ID, CF)	Coccidioides	75–90%	No validated urine antigen: serology is cornerstone	[2,5]
CF + immunodiffusion	Histoplasma	60–80%	May be negative early in immunocompromised	[13]
BAL GMS stain + culture	All three	Variable; culture = gold standard	Moderate-severe disease; slow turnaround	[11]
Tissue biopsy + GMS	All three	High (specimen-dependent)	Nodules or focal disease; inconclusive antigen/serology	[11]
PCR (emerging)	Histo, Blasto	Variable	Not yet guideline-endorsed; investigational	[13]

Table 1. Diagnostic toolkit for endemic mycoses. 

Test	Pathogen	Sensitivity	Clinical Notes	Ref.
Urine antigen EIA (MVista/IMMY)	Histoplasma	85–90% pulm.; >95% dissem.	First-line; same-day; cross-reacts with Blastomyces	[13]
Urine antigen EIA	Blastomyces	~90% moderate-severe	Always order with Histo antigen simultaneously	[13]
IgM + IgG serology (ID, CF)	Coccidioides	75–90%	No validated urine antigen: serology is cornerstone	[2,5]
CF + immunodiffusion	Histoplasma	60–80%	May be negative early in immunocompromised	[13]
BAL GMS stain + culture	All three	Variable; culture = gold standard	Moderate-severe disease; slow turnaround	[11]
Tissue biopsy + GMS	All three	High (specimen-dependent)	Nodules or focal disease; inconclusive antigen/serology	[11]
PCR (emerging)	Histo, Blasto	Variable	Not yet guideline-endorsed; investigational	[13]

8. Treatment Principles

Treatment selection is driven by disease severity, organism, and host immune status. Table 2 summarizes current guideline recommendations incorporating the 2025 IDSA Histoplasmosis Update [12].

9. Climate Projections and Future Burden

The Gorris et al. climate niche model - validated against 60 years of epidemiologic data - provides the most granular projection available for Coccidioides range expansion [6]. Under RCP 4.5 (moderate warming), 17 states are projected to be endemic by 2035; under RCP 8.5 (high emissions), endemicity may extend to 28+ states by 2100, exposing tens of millions of additional people. Analogous temperature-sensitivity data for Histoplasma suggest that even moderate warming will permit soil colonization in previously unsuitable northern latitudes.

10. Conclusions

The geographic boundaries that have governed clinical suspicion for endemic mycoses for half a century no longer reflect epidemiologic reality. All three major endemic fungi are now documented across virtually every US state, with locally acquired cases confirmed far outside historic zones. The drivers - climate change, expanding immunosuppressed populations, and improved diagnostics - are unlikely to reverse.

Three clinical imperatives emerge from this review: (1) test based on immune status - not zip code; (2) send urine antigen early and simultaneously for both Histoplasma and Blastomyces; and (3) break the steroid cascade before it begins. A urine antigen test costs $50–150; a missed diagnosis costs far more.